News

The latest from Cogstate, leaders in optimizing the measurement of cognition

Cogstate receives positive FDA notification regarding medical device regulatory submission

July 27, 2017

Company to launch COGNIGRAMTM digital cognitive testing tool in U.S. healthcare market Boston, MA – July 27, 2017: The cognitive science company, Cogstate today announced that its healthcare division has received notification from the U.S. Food and Drug Administration (FDA) that the Company’s 510(k) submission (K171658) for the COGNIGRAMTM cognitive assessment system has been reviewed […]

Pilot Study Demonstrates Working Memory Training May Be Effective For Children With Neurofibromatosis

June 27, 2017

While neurofibromatosis often appears in children as visible spots, freckles or tiny bumps, the genetic disorder can also cause learning disabilities, including problems with attention, working memory, inhibition and planning. Up to 40% of children with neurofibromatosis type 1 (NF1) are diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD). These symptoms can often cause issues at home […]

Cogstate Selected as Preferred Provider to Lilly’s Alzheimer’s Disease Platform

May 17, 2017

Company to Deliver Novel Solutions to Ensure High-quality Neuropsychological Measures in Clinical Trials New Haven, CT – May 17, 2017: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced it has been chosen as the preferred provider to the global healthcare leader, Eli Lilly and Company, to support their Alzheimer’s disease platform with solutions to ensure […]

Cogstate Brief Battery Effective For Detecting Cognitive Impairment in Pediatric MS Patients

May 12, 2017

While multiple sclerosis (MS) is most often diagnosed in adults, symptoms can begin much earlier in life. Pediatric onset MS (POMS) affects 8,000-10,000 children under the age of 18 in the U.S., while an additional estimated 10,000 have at least one symptom. Diagnosis can be difficult as physicians often default to more common childhood disorders […]

Cogstate Brief Battery Shows Correlation With Traditional Tests of Cognition In Breast Cancer Population

May 1, 2017

As the complexity and geographic distribution of clinical trials increase, there is a growing need for more efficient cognitive testing of participants. Traditional “pencil and paper” neuropsychological tests have been the gold standard but require expert administration and manual data collection. To scale to hundreds of patients located around the world, computerized cognitive testing offers […]

Cogstate Strengthens Executive Team with Appointment of Chief Technology Officer

March 15, 2017

New Haven, CT – March 15, 2017: The cognitive science company, Cogstate Ltd (ASX.CGS) announced today that Richard Gleeson has joined the senior leadership team as Chief Technology Officer, strengthening the company’s ability to deliver transformative innovations to optimize the measurement of cognition in clinical trials and healthcare. Reporting directly to Cogstate Chief Operating Officer, […]

AMPAR Potentiators May Have Role In The Treatment Of The Cognitive Symptoms Associated With Schizophrenia

March 15, 2017

Treating schizophrenia involves not only addressing the primary positive and negative symptoms but also the frequent cognitive dysfunction that accompanies the disorder, known as cognitive impairment associated with schizophrenia (CIAS). These deficits in attention, working memory and executive function have a detrimental impact on a patient’s quality of life and their functional capacity to manage […]

Cogstate Announces Appointment of Jane McAloon to Board of Directors

January 30, 2017

Cogstate Ltd (ASX.CGS) is pleased to announce the appointment of Jane McAloonas an Independent Non-Executive Director and, following release of the Appendix 4D Half Year Financial Report on 23 February 2017, Chair of the Audit & Compliance Committee of Cogstate Ltd. Until mid-2015, Jane was part of the Group Management Committee of BHP Billiton as […]

Cogstate Announces Appointment of Dr. Richard Mohs to Board of Directors

January 24, 2017

Cogstate Ltd (ASX.CGS) is pleased to announce the appointment of Dr. Richard Mohs as a non-executive director. Dr. Mohs retired from Eli Lilly in 2015, where he held several leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer’s Drug Development Team. Before joining Eli Lilly in 2002, Richard […]

Cognitive Decline and PTSD Symptoms Linked In Large Study Of Civilian Women

January 20, 2017

Living through a traumatic event is an unfortunate reality for many people with each episode resulting in varying recovery timelines and potentially long-term effects. When lasting effects result in daily challenges to normal activities, a diagnosis of post-traumatic stress disorder (PTSD) can trigger a treatment protocol of medications, counseling and support to help manage ongoing […]

Cogstate Announces New Executive Appointments For Clinical Trials And Healthcare Business Units

November 30, 2016

The cognitive science company, Cogstate Ltd (ASX.CGS) announced today two key appointments to executive positions. George Hunnewell has been named Chief Operating Officer of Cogstate and President of the Cogstate Clinical Trials division. Hunnewell, who previously served as Corporate Vice President, Clinical Research Services for Parexel International Corporation, will be responsible for the company’s worldwide […]

High Blood Pressure In Children Negatively Impacts Cognitive Performance

November 16, 2016

According to the Centers for Disease Control and Prevention, obesity among U.S. children and adolescents (aged 2-19) remained high between 2011 and 2014 at about 17%. Of these approximately 13 million young people, almost 10% are also diagnosed with primary hypertension, risking long-term cardiovascular organ damage as they move into adulthood. Beyond its physical effects, […]

Study Finds Brexpiprazole To Be An Effective Alternative To Aripiprazole

November 8, 2016

Despite the number of available antipsychotics, schizophrenia is still a complicated brain disorder to treat, in part due to the different side effects of various treatment regimens between patients. Brexpiprazole, a serotonin-dopamine activity modulator approved by the FDA for schizophrenia in 2015, was developed by Otsuka as a successor to aripiprazole, whose U.S. patent expired […]

Cogstate and Clinical Ink Deliver Enhanced Tablet-Based eCOA for CNS Clinical Trials

October 24, 2016

New Haven, CT & Philadelphia, PA– October 25, 2016: Cognitive science company, Cogstate Ltd (ASX.CGS) and Clinical Ink, the leading provider of eSource and patient engagement technologies, today announced they have formalized their long-standing relationship with a strategic alliance that delivers enhanced tablet-based neuropsychological assessments for CNS clinical trials. The alliance combines, in a single […]

Cogstate Computerized Battery Effective For Long-Term Monitoring of Cognitive Side Effects in Pediatric Leukemia Patients

October 20, 2016

Children with acute lymphoblastic leukemia (ALL) often battle neurocognitive deficits as a result of their radiation or chemotherapy treatment. During treatment and sometimes up to two years after treatment, their quality of life is affected by impairments in attention, processing speed and executive functioning. While many pediatric leukemia studies have identified possible counter measures later […]

1 2 3 7